Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles

AAPS PharmSciTech

Volumn 8, Issue 1, 2007, Pages

  Suresh, Gande ^a   Manjunath, Kopparam ^a   Venkateswarlu, Vobalaboina ^a   Satyanarayana, Vemula ^b  

^a KAKATIYA UNIVERSITY   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Differential scanning calorimetry; Lovastatin; Powder x ray; Solid lipid nanoparticles

Indexed keywords

MEVINOLIN; SIMVASTATIN; SOLID LIPID NANOPARTICLE; TRIACYLGLYCEROL; TRIPALMITIN; DRUG CARRIER; HYPOCHOLESTEROLEMIC AGENT; LIPID; LIPOSOME; NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; RAT; SLOW RELEASE FORMULATION; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG FORMULATION; DRUG SCREENING; EVALUATION; MATERIALS TESTING; METHODOLOGY; MICROCAPSULE; POWDER; WISTAR RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CAPSULES; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; LIPIDS; LIPOSOMES; LOVASTATIN; MALE; MATERIALS TESTING; NANOPARTICLES; PARTICLE SIZE; POWDERS; RATS; RATS, WISTAR;

EID: 34047232844     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0801024     Document Type: Article

References (29)

1. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751-757.
2. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32:403-425.
3. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm. 1998;167: 155-164.
4. 4 inhibitor. J Pharm Sci. 1998;87:164-169.
5. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev. 1998;34:221-233.
6. Bargoni A, Cavalli R, Caputo O, Fundaro A, Gasco MR, Zara GP. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res. 1998;15:745-750.
7. Eldridge JH, Hammond CJ, Meulbrock JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissue, I: orally administered biodegradable microspheres target the Peyer's patches. J Control Release. 1990;11:205-214.
8. Pappo J, Ermak TM, Steger HJ. Monoclonal antibody directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology. 1991;73:277-280.
9. Jepson MA, Simmons NL, O'Hagan DT, Hirst BH. Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target. 1993;1:245-249.
10. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev. 2001;47:55-64.
11. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci. 2003;92:1085-1094.
12. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95:627-638.
13. Wu Y, Zhao J, Henion J, Korfmacher WA, Lapiguera AP, Lin CC. Microsample determination of lovastatin and its hydroxy acid metabolite in mouse and rat plasma by liquid chromatography/ionspray tandem mass spectrometry. J Mass Spectrom. 1997;32:379-387.
14. Rajh SJ, Kreft S, Strukelj B, Vrecer F. Comparison of CE and HPLC methods for determining lovastatin and its oxidation products after exposure to an oxidative atmosphere. Croat Chem Acta. 2003;76:263-268.
15. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation x-ray diffraction. Int J Pharm. 1993;93:189-199.
16. Staggers JE, Hernell O, Stafford RJ, Carey MC. Physical-chemical behaviour of dietary and biliary lipids during intestinal digestion and absorption, I: phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry. 1990;29:2028-2040.
17. Yang SC, Zhu JB. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev Ind Pharm. 2002;28:265-274.
18. Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47:125-132.
19. zur Muhlen A, Schwarz C, Mehenert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanisms. Eur J Pharm Biopharm. 1998;45:149-155.
20. Jenning V, Thunemann AF, Gohla SH. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199:167-177.
21. Jesser WA, Shneck RZ, Gile WW. Solid-liquid equilibria in nanoparticles of Pb-Bi alloys. Phys Rev B. 2004;69:1-13.
22. Cavalli R, Aquilano D, Carrlotti ME, Gasco MR. Study by x-ray powder diffraction and differential scanning calorimetry of two model drugs, phenothiazine and nifedipine, incorporated into lipid nanoparticles. Eur J Pharm Biopharm. 1995;41:329-333.
23. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm. 1997;148:47-54.
24. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev. 1998;34:135-154.
25. Andrianov AK, Payne LG. Polymeric carriers for oral uptake of microparticulates. Adv Drug Deliv Rev. 1998;34:155-170.
26. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50:3-20.
27. Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release. 1995;36:39-46.
28. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev. 1991;7:71-86.
29. Florence AT, Hillery M, Jani PU. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target. 1995;3:65-70.